Denial Risk — Unsupported Indications

Testing for onychomycosis may be denied when performed for indications that are not consistent with the medical necessity criteria or when results would not affect clinical management. Do not order microscopy, culture, or molecular testing for screening or for conditions where onychomycosis is not suspected.

• Denial risk if documentation does not show signs/symptoms of onychomycosis (discolored, deformed, brittle, foul-smelling nails; subungual debris; nail separation).
• Denial risk if testing is ordered for screening, cosmetic concerns, or other unsupported indications.
• Denial risk if test results would not influence treatment decisions.

Required Clinical Documentation

Document the clinical signs and symptoms that support a suspected diagnosis of onychomycosis and the clinical rationale for testing. Clear documentation helps demonstrate medical necessity and supports coverage.

• Signs/symptoms to document: nails that are discolored, deformed, brittle, hypertrophic or hyperkeratotic; subungual debris; separation from the nail bed; nails that are foul smelling.
• Clinical note must state how test results will influence management (e.g., to confirm diagnosis prior to systemic antifungal therapy or to identify organism when response to prior therapy is inadequate).
• Specify the specimen site (toenail vs fingernail), prior treatments, and relevant clinical history.

Documentation of Medical Necessity

Follow the Health Plan's administrative policies for demonstrating medical necessity and include supporting documentation with claims or prior authorization requests when applicable.

• Provide medical records, progress notes, diagnostic rationale, and lab requisitions showing the clinical indication.
• If prior authorization is required by the member's benefit plan, obtain approval before performing non-emergent testing.
• Failure to supply requested documentation may result in claim denial or retrospective review.